Skip to main
  1. Stocks
  2. Danaher
  3. Forecast
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is attractive because its post-Veralto portfolio is now concentrated in higher-quality life sciences and diagnostics franchises with durable demand, recurring consumables revenue, and improving bioprocessing trends that support a credible path to 5-7% revenue growth and HSD-DD% EPS growth. The company also showed solid execution in 3Q26, with $6.55B of revenue, 3.0% core growth, 29.0% adjusted operating margin, and $2.11 of adjusted EPS, while free cash flow of $1.6B and 128% FCF-to-net-income conversion underscored earnings quality. Despite a conservative 2027 outlook and lingering headwinds in respiratory and China, the reported order strength, durable underlying demand, and continued capital deployment potential suggest further upside as end markets recover.

Bears say

Danaher is facing a difficult fundamental backdrop because key end markets are softening, including reduced spending from biopharmaceutical companies, lower government funding for research, and weaker purchases by hospital labs and clinics. The company’s bioprocess equipment recovery has been slow, with promised reshoring-related demand not yet showing up, while Life Sciences instrument demand continues to decline and diagnostics in China still weighs on results, even though sales there are now under $1B annually and pricing pressure has eased. Investor skepticism is also rising around acquisition execution, as several recent Life Sciences deals have failed to meet expectations, making a 15x P/E downside multiple plausible if growth frustrations persist.

Danaher (DHR) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Danaher (DHR) Analyst Forecast & Price Prediction

Get the latest Danaher (DHR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Danaher (DHR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 16 analysts, Danaher (DHR) has a Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $245.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $245.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Danaher (DHR) Analyst Forecast & Price Prediction

Get the latest Danaher (DHR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Danaher (DHR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DHR stock data and trends